Our Speakers
Discover the pioneering minds headlining the Borealis Psychedelic Science Summit 2025. Below, you’ll find our growing roster of experts. Click on each speaker to learn more about their background, their summit topic, and the insights they’ll share in Stockholm. We’ll be updating this page as more speakers are confirmed, so check back often.
Cecilie B. Endresen (NAPSi) is a psychologist and advocate for ethical, inclusive psychedelic science, bridging clinical work, ecology, and leadership
Psychologist and researcher focused on psychedelic integration, harm reduction, and clinical support, currently leading a national study in Poland.
Dr. Paul Liknaitzky, leading psychedelic researcher at Monash, spearheads transformative clinical trials and novel therapies in Australia.
Dr. Gerhard Gründer, psychiatrist at CIMH Mannheim, pioneers advanced imaging and psychedelic research in severe mental disorders.
Dr. Julie Holland, NYT-bestselling psychiatrist and MAPS advisor, pioneers MDMA and cannabis-assisted therapies.
Josh Hardman, founder of Psychedelic Alpha, offers data-driven insights on psychedelics, spanning business, policy, and research.
Dr. Maria Beckman, psychologist at Karolinska, researches psilocybin therapies and therapist–patient dynamics in clinical trials.
Dr. Leor Roseman, researcher at University of Exeter, merges neuroscience, anthropology, and conflict resolution in psychedelic studies.
Dr. David Nutt, Prof. of Neuropsychopharmacology at Imperial College, pioneers breakthroughs from GABA to psychedelics.
Dr. Christoffer Timmermann, researcher at University College London, leads the DMT Research Group exploring psychedelics’ effects on brain and mind.
Licensed psychologist specialized in neuropsychology, active in psilocybin research, therapy training, and psychedelic integration.
MD and PhD student studying psilocybin for cancer-related depression, focusing on clinical effects, expectancy, and brain changes in CAPSI trial.
Dr. Hendricks studies psilocybin for addiction, pain, and demoralization, focusing on vulnerable groups and leads multiple clinical trials at UAB.
Oxford psychiatrist researching mood disorders and psychedelics; led Compass Pathways' phase IIb trial and is among the top 1% most cited researchers.
Prof. Schoevers studies mood disorders and psychedelic treatments, leads the PsyPal trial on psilocybin in palliative care and pioneers esketamine use
Psychologist and researcher in Zurich and Basel studying psychedelics; also practices PAT and trains therapists through the Swiss Medical Association.
Prof. Camilla Lindvall Dahlgren (ONH) researches eating disorders and leads work on ketamine-assisted therapy and clinical innovation in Norway.
Dr. Lowan Stewart is a leading expert in ketamine and psychedelic therapies, co-founding clinics and research groups across Norway and the U.S.
Dr. Rebecca Böhme (Linköping Univ.) studies the sense of self through neuroscience, brain imaging, and psychedelic interventions.
Dr. Matthew W. Johnson (Johns Hopkins) is a leading psychedelic researcher, known for work on psilocybin, addiction, and behavioral pharmacology.
Dr. Kangaslampi (Tampere Univ.) researches trauma, memory, and psychedelics, and holds leadership roles in key Finnish psychological associations.
Dr. Jason Luoma researches shame and connection, combining ACT and psychedelic therapy to foster compassion and belonging.
Dr. Jussi Jylkkä (Åbo Akademi) researches psychedelic insights, belief change, their place within cognitive psychology and the scientific worldview.
Prof. Gitte Moos Knudsen (Rigshospitalet/Copenhagen) studies brain disorders and treatment response using PET, fMRI, and precision neuroimaging.
Dr. Dea Stenbæk researches psilocybin’s effects on the brain, focusing on serotonin, neurocognition, and therapeutic setting using PET imaging.
Ulf Bremberg (Osmond Labs) coordinates EU-funded psilocybin research and works to advance psychedelic therapy integration in healthcare.
Prof. Suresh Muthukumaraswamy (Univ. of Auckland) studies how psychedelics and therapies alter brain function, leading large trials on LSD & ketamine.
Dr. Ingrid Autran (Østfold Hospital) researches ketamine and MDMA therapy, and founded harm-reduction group Safe Space and Aurora Clinics.
Ian Roullier co-founded PsyPAN to center participant voices in psychedelic care, drawing on his lived experience in psilocybin trials and advocacy.
Dr. Eva Henje researches youth depression, trauma therapies, and MDMA-assisted treatment, with clinical roles in Sweden, Oslo, and the Netherlands.
Dr. Balazs Szigeti pioneers citizen science in psychedelics, leading the largest microdosing study with his novel self-blinding methodology.